Insulet Corporation, a developer of tubeless insulin pump technology with its Omnipod Insulin Management System, has appointed Michael R. Minogue and James C. Mullen to its Board of Directors. Insulet executives also announced that Regina Sommer and Joseph Zakrzewski have retired from the board.
 
“We are delighted to welcome Mike and Jim to the Insulet Board,” said Patrick Sullivan, chairman and CEO. “Both are accomplished executives with impressive track records in the healthcare and biotech industries. They bring global leadership experience to Insulet and are outstanding and highly-complementary additions to the Board as we execute our global strategic growth initiatives. Insulet has been well served by Reggie’s and Joe’s long-standing dedication and contributions. Their active engagement throughout their tenure has advanced the company’s growth and success, and we sincerely thank them for their years of valued service.”
 
Minogue is CEO, president and chairman of Abiomed Inc., a healthcare technology developer. A seasoned business executive with more than two decades of experience, he joined Abiomed from GE Healthcare, where he holds three patents and spent 11 years developing expertise in sales, marketing, product development, information technologies and software/service operations. He currently serves on the Board of Directors of the Advanced Medical Technology Association, chairs the Medical Device Innovation Consortium, and chaird the Governor’s Advisory Council on Veterans’ Services for the Commonwealth of Massachusetts.

Minogue is also on the Board of Managers for Bioventus LLC and recently stepped down from his position as chairman after concluding 10 years of service on the Board of Directors for MassMEDIC. He is the co-founder and chairman of the Mentoring Veterans Program (MVPvets), a nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the life sciences industries. He served as an Infantry officer in the U.S. Army, which included multiple distinctions, including Airborne Ranger, Desert Storm veteran and he was awarded the Bronze Star. Minogue received a bachelor of science degree in engineering management from the United States Military Academy at West Point and an MBA from the University of Chicago.
 
Mullen, a 30-year veteran of the biotech industry, is CEO of Patheon N.V., a global provider of pharmaceutical development and manufacturing services; the company recently announced an agreement to be acquired by Thermo Fisher Scientific Inc. Prior to joining Patheon, from 2003 to 2010, Mullen served as CEO and president at Biogen, one of the world’s largest biotechnology companies. Mullen held various operating positions at Biogen prior to becoming CEO, including vice president, Operations, as well as several key manufacturing and engineering positions, and spent over nine years at SmithKline Beecham. His areas of expertise include biotechnology, pharmaceuticals, specialty chemicals, manufacturing, engineering, sales and marketing. He previously served on the Board of Directors of PerkinElmer and also as chairman of the Biotechnology Innovation Organization. Mullen received a bachelor of science degree in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.
 
Insulet Corporation is dedicated to expanding the use of insulin pump therapy with its Omnipod Insulin Management System among diabetics. The Omnipod System is a tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Mass.